Pakkala Suchita, Ramalingam Suresh S
Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia, USA.
Curr Opin Oncol. 2016 Mar;28(2):150-8. doi: 10.1097/CCO.0000000000000269.
In this article, we discuss the emergence of adjuvant chemotherapy as the standard of care, the potential role of targeted and immune therapy in resected nonsmall cell lung cancer (NSCLC) patients, and the importance of ongoing clinical trials to further define the use of these agents as adjuvant therapy.
Adjuvant chemotherapy after surgical resection provides modest improvements in cure rate, though recurrence of disease still occurs in a substantial proportion of patients. The advent of targeted and immune therapies has improved outcomes for patients with advanced stage NSCLC. Recent studies have explored the role of vascular endothelial growth factor inhibitors, epidermal growth factor receptor tyrosine kinase inhibitors, vaccine therapy, and predictive biomarkers in the adjuvant setting.
Platinum doublet chemotherapy remains the standard adjuvant therapy for resected stage II, IIIA, and high-risk stage IB NSCLC. Ongoing clinical trials are evaluating emerging therapies to improve efficacy and reduce toxicity while aiming to improve patient selection for such therapies.
在本文中，我们讨论辅助化疗作为标准治疗方法的出现、靶向治疗和免疫治疗在可切除非小细胞肺癌（NSCLC）患者中的潜在作用，以及正在进行的临床试验对于进一步明确这些药物作为辅助治疗的使用的重要性。
手术切除后进行辅助化疗可适度提高治愈率，不过仍有相当比例的患者会出现疾病复发。靶向治疗和免疫治疗的出现改善了晚期NSCLC患者的预后。最近的研究探讨了血管内皮生长因子抑制剂、表皮生长因子受体酪氨酸激酶抑制剂、疫苗治疗以及预测性生物标志物在辅助治疗中的作用。
铂类双联化疗仍然是可切除的II期、IIIA期和高危IB期NSCLC的标准辅助治疗方法。正在进行的临床试验正在评估新兴疗法，以提高疗效并降低毒性，同时旨在改善此类疗法的患者选择。
